The successful development of new vaccines depends on the interaction of industrial expertise for vaccine design and engineering with academic understanding of the mechanisms of protection afforded by the immune responses they eli...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
INCENTIVE
Indo European Consortium for Next Generation Influenza Vacci...
20M€
Cerrado
ESI-TBVI
Establishment Strategy and Initial activities of the TuBerc...
520K€
Cerrado
INYVAX
Optimisation of the development of Poverty Related Diseases...
1M€
Cerrado
SAF2008-02036
BIOLOGIA DEL VIRUS VACCINIA Y SU APLICACION COMO VACUNA CONT...
655K€
Cerrado
SAF2013-45232-R
VACUNAS FRENTE A ENFERMEDADES HUMANAS PREVALENTES Y OPTIMIZA...
593K€
Cerrado
EHVA
European HIV Vaccine Alliance EHVA a EU platform for the...
28M€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The successful development of new vaccines depends on the interaction of industrial expertise for vaccine design and engineering with academic understanding of the mechanisms of protection afforded by the immune responses they elicit. Close interaction between both sectors expedites vaccine development and, in the context of global health, this can translate to the saving of thousands of lives. The VADER (Vaccine Design and Immune Responses) EID programme, established between the Novartis Vaccines Institute for Global Health (NVGH) in Italy and University of Birmingham (UoB) in the UK, will train four talented clinical and non-clinical fellows at the interface between academia and industry. NVGH is a company with a mission to develop affordable and effective vaccines against infectious diseases of impoverished communities in the developing world. Its first vaccine, against Salmonella Typhi, is in clinical trails in South-East Asia, with vaccines against Salmonella Paratyphi, nontyphoidal Salmonella, meningococcus and Shigella in preclinical development. UoB is an international leader in investigating immune responses to bacteria, particularly Salmonellae, and in relating immunity to microbial antigens. The two institutions have forged strong links over the last year which form the framework of the VADER programme. The fellows will work on four related projects embedded within existing vaccine programmes at NVGH where they will work as part of a team of scientists. With vaccines in clinical trials, trainees will be able to explore immune responses in human vaccinees as well as animals. In their projects, they will be trained in vaccine design and immunology and learn how differences in vaccine engineering affect immune responses. By working on both industrial and academic sides of vaccine development they receive a research training in translational and transferable skills and learn how both sectors can synergise in vaccine development.